Home Oncology • Anticancer agents : frontiers in cancer chemotherapy by Iwao Ojima, Gregory D. Vite, Karl-Heinz Altmann

Anticancer agents : frontiers in cancer chemotherapy by Iwao Ojima, Gregory D. Vite, Karl-Heinz Altmann

By Iwao Ojima, Gregory D. Vite, Karl-Heinz Altmann

Melanoma drug discovery and improvement : new paradigms for a brand new millennium / E.A. Sausville ... [et al.] --
Evolutionary biosynthesis of anticancer medicinal drugs / George R. Pettit --
Some contemporary advancements within the synthesis and structure-activity courting of novel taxanes / John F. Kadow ... [et al.] --
New new release taxoids and hybrids of microtubule-stabilizing anticancer brokers / Iwao Ojima ... [et al.] --
Discodermolide and taxol : a synergistic drug mix in human carcinoma cellphone strains / Susan Band Horwitz ... [et al.] --
Highly effective semisynthesis of biologically energetic epothilone derivatives / Gregory D. Vite ... [et al.] --
Synthetic and semisynthetic analogs of epothilones : chemistry and organic task / Karl-Heinz Altmann ... [et al.] --
Synthesis and organic task of epothilones / Ulrich Klar ... [et al.] --
Epothilones and sarcodictyins : from combinatorial libraries to designed analogs / Nicolas Winssinger and K.C. Nicolaou --
Synthesis and structure-activity dating reviews of cryptophycins : a singular category of powerful antimitotic antitumor depsipeptides / Chuan Shih ... [et al.] --
Farnesyltransferase inhibitors as strength anticancer brokers / J.B. Gibbs ... [et al.] --
Farnesyltransferase inhibitors : from squalene synthase inhibitors to the scientific agent BMS-214662 / John T. Hunt --
Inhibiting farnesyl protein transferase with Sch-66336 : probably a selective noncytotoxic remedy for human melanoma / A.G. Taveras ... [et al.] --
Pyrrolo[2,3-d]pyrimidine and pyrazolo[3,4-d]pyrimidine derivatives as selective inhibitors of the EGF receptor tryosine kinase / G. Caravatti ... [et al.] --
STI571 : a brand new therapy modality for CML? / Jürg Zimmermann, Pascal Furet, and Elisabeth Buchdunger --
The discovery and improvement of second-generation matrix metalloproteinase inhibitors for the therapy of melanoma / Andy Baxter and John Montana --
Prospects for antiangiogenic treatments established upon VEGF inhibition / Pascal Furet and Paul W. Manley --
Carbohydrate-based tumor antigens as antitumor vaccine brokers / Jennifer R. Allen and Samuel J. Danishefsky --
Drugs to augment the healing efficiency of anticancer antibodies : antibody-drug conjugates as tumor-activated prodrugs / Walter A. Blättler and Ravi V.J. Chari

Show description

Read or Download Anticancer agents : frontiers in cancer chemotherapy PDF

Best oncology books

Improving the Quality of Cancer Clinical Trials: Workshop Summary

Scientists and clinicians search a brand new paradigm which can increase the potency, cost-effectiveness, and total good fortune price of melanoma medical trials, whereas preserving the top criteria of caliber. To discover cutting edge paradigms for melanoma scientific trials and alternative routes to enhance their caliber, the nationwide melanoma coverage discussion board held a workshop, bettering the standard of melanoma medical Trials, in Washington, DC.

Methods of Cancer Diagnosis, Therapy and Prognosis Vol. 4: Colorectal Cancer

This fourth quantity within the sequence equipment of melanoma analysis, treatment and analysis discusses quite a few methodologies for the prognosis, treatment and diagnosis of Colorectal melanoma. either common and rising cures for this melanoma, written by way of professional oncologists/pathologists during this box, are integrated.

WHO Classification of Tumours of hematopoietic and lymphoid tissues 4th edition

WHO type of Tumours of Haematopoietic and Lymphoid Tissue is the 3rd quantity within the new WHO sequence on histological and genetic typing of human tumors. This authoritative, concise reference publication covers the full diversity of leukaemias and lymphomas. It presents a world regular for oncologists and pathologists and may function an necessary consultant to be used within the layout of stories tracking reaction to remedy and medical final result.

Oral Complications of Cancer and its Management

Oral difficulties are universal in melanoma sufferers. they could be a a part of the illness itself; they could boost due to therapy; they could accompany different indicators and current as a comorbidity; they usually also can first current after the unique sickness itself has been cured. Oral signs should be advanced to regard, either combating management of probably life-saving remedy, and likewise without delay inflicting extra life-threatening problems.

Extra info for Anticancer agents : frontiers in cancer chemotherapy

Example text

Zhuang, L . Tetrahedron Lett. 1997, 38, 8675-8678. Pettit, G . ; Cichacz, Ζ. ; Herald, C . ; Boyd, M. R. J. Chem. Soc, Chem. Commun. 1993, 14, 1166-1168. Pettit, G . ; Herald, C . ; Cichacz, Ζ. ; Schmidt, J. ; Boyd, M. ; Christie, N. D . ; Boettner, F . E . J. Chem. Soc. Chem. Commun. 1993, 1805-1807. Pettit, G . ; Herald, C . ; Cichacz, Ζ. ; Gao, F . ; Boyd, M. ; Christie, N. D . ; Schmidt, J. M. Nat. Prod. Lett. 1993, 3, 239-244. Pettit, G . ; Cichacz, Ζ. ; Herald, C . ; Gao, F . ; Boyd, M.

Thus we relied on our knowledge of the highfield NMR characteristics of the components to direct the total synthetic approaches. Each of the total syntheses we completed required about 28 steps; they were not easy at the beginning and it took 15 total syntheses (114,115) to prepare the natural product, a definite improvement over the theoretical 512! Subsequently, we prepared dolastatin 10 for clinical trials by total synthesis, and NCI phase II cancer clinical trials are under way. Current results indicate, for example, a good future in the treatment of refractory A M L .

MDR resistant human colon tumor cell line. Ratio of I C for HCT 116(VM)46 MDR resistant cell line /IC for HCT 116 sensitive cell line. Paclitaxel sensitive human ovarian tumor cell line. ^Paclitaxel resistant human ovarian tumor cell line known to be resistant due to a β-tubulin mutation (T. Fojo, NCI(23)). g Ratio of I C for human ovarian resistant cell line /IC for A2780 senstive cell line. b C d 50 50 e 50 50 against an ip/ip M109 tumor model(16). This initial in vivo screen minimizes the impact of pharmokinetics since both the tumor and drug are placed in the intraperitoneal cavity and provides initial indications of activity and potency.

Download PDF sample

Rated 4.72 of 5 – based on 5 votes